Point72 DIFC Ltd Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Point72 DIFC Ltd boosted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 8.4% in the third quarter, HoldingsChannel reports. The fund owned 43,789 shares of the company’s stock after purchasing an additional 3,376 shares during the quarter. Point72 DIFC Ltd’s holdings in Vera Therapeutics were worth $1,935,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. William Marsh Rice University purchased a new stake in Vera Therapeutics during the second quarter valued at approximately $593,000. Renaissance Technologies LLC increased its stake in Vera Therapeutics by 28.5% during the 2nd quarter. Renaissance Technologies LLC now owns 147,800 shares of the company’s stock valued at $5,347,000 after purchasing an additional 32,800 shares in the last quarter. First Turn Management LLC increased its stake in Vera Therapeutics by 53.3% during the 3rd quarter. First Turn Management LLC now owns 326,494 shares of the company’s stock valued at $14,431,000 after purchasing an additional 113,550 shares in the last quarter. Magnetar Financial LLC acquired a new position in Vera Therapeutics during the 2nd quarter valued at approximately $652,000. Finally, Victory Capital Management Inc. increased its stake in Vera Therapeutics by 202.4% during the 2nd quarter. Victory Capital Management Inc. now owns 33,707 shares of the company’s stock valued at $1,220,000 after purchasing an additional 22,560 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 0.2 %

VERA stock opened at $49.46 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The firm’s fifty day moving average is $44.37 and its 200 day moving average is $39.86. Vera Therapeutics, Inc. has a one year low of $13.09 and a one year high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.21). On average, sell-side analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analysts Set New Price Targets

VERA has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Evercore ISI upgraded shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank initiated coverage on shares of Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. Finally, Guggenheim increased their price objective on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Monday, October 28th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $59.22.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total transaction of $49,445.77. Following the transaction, the director now directly owns 160,376 shares of the company’s stock, valued at $6,737,395.76. This trade represents a 0.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the transaction, the chief executive officer now directly owns 307,972 shares in the company, valued at approximately $11,548,950. The trade was a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 89,927 shares of company stock worth $3,800,796. 21.70% of the stock is owned by company insiders.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.